Special Issue "Neurological Symptoms and COVID-19 Pandemic"
Deadline for manuscript submissions: 10 October 2023 | Viewed by 24815
Interests: brain; medicine; glioblastoma; spine; hydrocephalus; brain tumor; surgery; diabetes; trauma; vascular
Special Issues, Collections and Topics in MDPI journals
Special Issue in International Journal of Environmental Research and Public Health: Brain Tumors, New Technologies and Augmented Reality
Special Issue in Neurology International: Stroke: From Pathophysiology to Therapy
Special Issue in Neurology International: Glioblastoma: Mechanics of Development, Progression and New Surgical and Clinical Management
Interests: exosomes; liquid biopsy; brain malignancies; degenerative disc disease; 3D printed models; craniofacial reconstructions; gait analysis; spine disorder
Interests: functional neurosurgery; cerebrovascular disease; neuro-oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue in Cancers: Outcomes in Glioblastoma Patients: From Diagnosis to Palliation
The current COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread across the world. Patients typically present with fever, shortness of breath and cough, but some patients develop neurological sequelae, such as headache and neuroinflammatory or cerebrovascular disease, and these conditions are more frequent in patients with severe COVID-19. Effective vaccines against SARS-CoV-2 have been rapidly developed and are being administered with the aim of preventing COVID-19, stopping viral circulation and terminating the pandemic.
COVID-19 induces an inflammatory response and, in severe cases, a cytokine storm that can damage the CNS. The ability of COVID-19 to produce a cytokine storm and inflammation might be at the center of the pathogenicity of the virus; however, little is known about this virus. This Special Issue will contribute significantly to the development of anti-COVID-19 strategies by collecting and publishing innovative concepts, suggestions and research data for the identification and validation of specific drug targets and cell-mediated immunity.
In addition, patients with COVID-19 infection are at increased risk for thrombotic events as various anticoagulation regimens are now being considered for these patients, and different types of vaccines are not free from side effects and intracranial complications. Endothelial dysfunction, activation of the renin–angiotensin–aldosterone system (RAAS) with the release of procoagulant plasminogen activator inhibitor (PAI-1) and hyperimmune responses with activated platelets seem to be significant contributors to thrombogenesis in COVID-19.
We welcome original papers, systematic reviews, and reviews on this interesting and current topic that lay emphasis on neuroinflammation, specific drug targets, hyperimmune responses and clinical neurological symptoms.
We look forward to your contributions.
Dr. Nicola Montemurro
Dr. Luca Ricciardi
Dr. Alba Scerrati
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- intracranial hemorrhage
- drug targets
- hyperimmune response
- side effects
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Herbal medicines in reducing the neurological symptoms of COVID-19 infection and post-vaccination symptoms
Authors: Gerard Nowak
Affiliation: Poznan University of Medical Sciences Poznan Poland
Abstract: in the introduction to our publication, we will present the neurological symptoms of COVID-19 infection and what are the neurological symptoms of the vaccines used, after all, COVID-19. Then we would like to present plant raw materials with proven clinical methods of action: antidepressant, anxiolytic and in mixed anxiety-depressive syndromes. Moreover, the description of the herbal medicine would present the formulas of the main active compounds responsible for the therapeutic effect, their side effects and their possible use in the elderly.